



UnitedHealthcare Community Plan Pharmacy & Therapeutics Committee Minutes

Meeting Date: September 9, 2021

Location: Via conference call/Teams

| Agenda Item | Speaker | Recommendation | Conclusions/Recommendations | Vote |
|--|---------------|---|---|------|
| Meeting called to order | G. Shutzberg | 5:03 PM | | |
| A. Introduction - Minutes from previous meeting | G. Shutzberg | Review of Minutes from June 17, 2021 | Minutes reviewed, approved | Yes |
| A. Introduction - P&T Committee Updates | G. Shutzberg | Review of non-solid dosage forms: Reviewed as a follow-up from the June P&T meeting where there was discussion of increasing the maximum age edit for non-solid dosage forms from 8 years to 10 or 12 years. Upon further review, the recommendation at this time is to keep the maximum age edit at 8 years. | Non voting item | Yes |
| B. Formulary Review - New Drugs | M. Reisman | Fotivda Recommendation: • Non-preferred with prior authorization across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | M. Reisman | Zegalogue Recommendation: • Preferred across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | C. Lichtinger | Ponvory Recommendation: • Non-preferred with prior authorization across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | C. Lichtinger | Accrufer Recommendation: • Non-preferred with prior authorization across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | G. Shutzberg | Nextellis Recommendation: • Non-preferred with prior authorization across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| B. Formulary Review - Class Reviews | G. Shutzberg | Attention Deficit Hyperactivity Disorder (ADHD): Azstarys and Qelbree Confirm class review | Yes/No | Yes |
| | | Recommendation: • Azstarys: Non-preferred with prior authorization across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Recommendation: • Qelbree: Non-preferred with prior authorization across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| B. Formulary Review- New Formulations | G. Shutzberg | Confirm Review of New Formulations Grid Recommendation: • Hetlioz LQ: Non-preferred with prior authorization across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Recommendation: • Helidac Therapy: Non-preferred with prior authorization across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |

| Agenda Item | Speaker | Recommendation | Conclusions/Recommendations | Vote |
|---|--------------|---|---|------|
| B. Formulary Review - PDL Modifications | G. Shutzberg | Confirm Review of PDL Modifications Grid | Yes/No | Yes |
| | | Recommendation: • Anoro Ellipta Powder for Inhalation: Move to preferred across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Recommendation: • Budesonide/Formoterol inhalation aerosol (Symbicort Authorized Generic): Move to preferred with prior authorization across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Recommendation: • Trulance tablet: Move to non-preferred with prior authorization across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Recommendation: • Modafinil tablet: Move to preferred with Dx2Rx (diagnosis check) across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Recommendation: • Dexmethylphenidate IR tablet: Move to preferred with Dx2Rx (diagnosis check) across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Recommendation: • Dexmethylphenidate ER capsule: Move to preferred with Dx2Rx (diagnosis check) across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Recommendation: • PEG-3350 Electrolytes powder for solution: Move to preferred across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Recommendation: • Gavilyte-G powder for solution: Move to preferred across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Recommendation: • Gavilyte-H: Move to preferred across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Recommendation: • Ivermectin tablet: Move to preferred with Dx2Rx (diagnosis check) across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Recommendation: • Prenatal Multivitamins: Products identified as cost outliers will be moved to non-preferred with prior authorization across all applicable lines of business. Products that are comparably priced to other preferred products will be moved to preferred across applicable lines of business. | Currently on hold for voting at this time | |
| B. Formulary Review - New Drugs- Medical | M. Reisman | Confirm Review of New Drugs- Medical Grid | Yes/No | Yes |
| | | Amondys 45 | | |
| | | Recommendation: • Medical benefit with prior authorization required across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Cosela | | |
| | | Recommendation: • Medical benefit across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Evkeeza | | |
| | | Recommendation: • Medical benefit with prior authorization required across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Margenza | | |
| | | Recommendation: • Medical benefit with prior authorization required across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Nulibry | | |
| | | Recommendation: • Medical benefit across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |

| Agenda Item | Speaker | Recommendation | Conclusions/Recommendations | Vote |
|--|---|---|---|------|
| B. Formulary Review - New Drugs- Medical (cont.) | M. Reisman | Pepaxto | | |
| | | Recommendation: • Medical benefit with prior authorization required across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Abecma | | |
| | | Recommendation: • Medical benefit with prior authorization required across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Artesunate | | |
| | | Recommendation: • Medical benefit across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Jemperli | | |
| Recommendation: • Medical benefit with prior authorization required across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 | | |
| Zynlonta | | | | |
| Recommendation: • Medical benefit with prior authorization required across all applicable lines of business | Motion made, seconded, and carried to accept recommendation | 9:0 | | |
| B. Formulary Review - Drugs Evaluated Per Grid | G. Shutzberg | Apply recommendations as outlined in grid | Motion made, seconded, and carried to accept recommendation | 9:0 |
| C. Clinical Guidelines | G. Shutzberg | Clinical Guideline Review | | |
| | | Apply New Pharmacy Guidelines | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Continue to Apply Pharmacy Guidelines Requiring Modifications | Motion made, seconded, and carried to accept recommendation | 9:0 |
| | | Remove Pharmacy Guidelines Requiring Archival | Motion made, seconded, and carried to accept recommendation | 9:0 |
| D. Quality Monitoring | L. Smith/M. Reisman | Confirm Review of Quality Data | Yes/No | Yes |
| | L. Smith | DUR Review | | |
| | M. Reisman | Top 25 Drugs by Cost and Volume – 2nd Quarter 2021 | | |
| | Comment: | • Discussion was held regarding the cost of the Pfizer vaccine displayed on the slide. Confirmed that the cost is the administration fee. | | |
| | M. Reisman | Top 10 Drugs Requested - Approvals and Denials – 2nd Quarter 2021 | | |
| | M. Reisman | Grievances and Appeals Data – 2nd Quarter 2021 | | |
| | M. Reisman | Inter-Rater Reliability (IRR) – 2nd Quarter 2021 • Pharmacists | | |
| Adjournment | G. Shutzberg | | 6:15 PM | |
| Comments: • Carl Tepper documented a question on his tally to see if we review reporting on high number of prescription drugs. | | | | |

Respectfully Submitted to the Committee,



James P. Hancovsky, M.S.I.A., R.Ph.
Chief Pharmacy Officer, UHC C&S